96 related articles for article (PubMed ID: 11804276)
1. Technology evaluation: MG-98, MethylGene.
Zhang Z
Curr Opin Mol Ther; 2001 Dec; 3(6):599-604. PubMed ID: 11804276
[TBL] [Abstract][Full Text] [Related]
2. GTI-2040. Lorus Therapeutics.
Orr RM
Curr Opin Investig Drugs; 2001 Oct; 2(10):1462-6. PubMed ID: 11890366
[TBL] [Abstract][Full Text] [Related]
3. Technology evaluation: ISIS-2503, Isis Pharmaceuticals.
Morse MA
Curr Opin Mol Ther; 2001 Dec; 3(6):589-94. PubMed ID: 11804274
[TBL] [Abstract][Full Text] [Related]
4. AEG-35156, an antisense oligonucleotide against X-linked inhibitor of apoptosis for the potential treatment of cancer.
Tamm I
Curr Opin Investig Drugs; 2008 Jun; 9(6):638-46. PubMed ID: 18516763
[TBL] [Abstract][Full Text] [Related]
5. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
6. Genasense (Genta Inc).
Banerjee D
Curr Opin Investig Drugs; 2001 Apr; 2(4):574-80. PubMed ID: 11566020
[TBL] [Abstract][Full Text] [Related]
7. GTI-2501. Lorus Therapeutics.
Tu GC; Tu X
Curr Opin Investig Drugs; 2001 Oct; 2(10):1467-70. PubMed ID: 11890367
[TBL] [Abstract][Full Text] [Related]
8. Trabedersen, a TGFbeta2-specific antisense oligonucleotide for the treatment of malignant gliomas and other tumors overexpressing TGFbeta2.
Vallières L
IDrugs; 2009 Jul; 12(7):445-53. PubMed ID: 19579166
[TBL] [Abstract][Full Text] [Related]
9. Antisense oligonucleotide-based therapeutics for cancer.
Dean NM; Bennett CF
Oncogene; 2003 Dec; 22(56):9087-96. PubMed ID: 14663487
[TBL] [Abstract][Full Text] [Related]
10. Antisense strategies for oncogene inactivation.
Stein CA; Benimetskaya L; Mani S
Semin Oncol; 2005 Dec; 32(6):563-72. PubMed ID: 16338422
[TBL] [Abstract][Full Text] [Related]
11. GEM-231 (Hybridon).
Blay J
IDrugs; 2000 Sep; 3(9):1075-80. PubMed ID: 16049867
[TBL] [Abstract][Full Text] [Related]
12. Preclinical and clinical experience of antisense therapy for solid tumors.
Webb MS; Zon G
Curr Opin Mol Ther; 1999 Aug; 1(4):458-63. PubMed ID: 11713760
[TBL] [Abstract][Full Text] [Related]
13. Technology evaluation: GEM-231, Hybridon Inc.
Blay J
Curr Opin Mol Ther; 2000 Aug; 2(4):468-72. PubMed ID: 11249779
[TBL] [Abstract][Full Text] [Related]
14. Technology evaluation: GEM-231, Hybridon.
Yeung PK
Curr Opin Mol Ther; 2003 Jun; 5(3):315-20. PubMed ID: 12870443
[TBL] [Abstract][Full Text] [Related]
15. [Antisense oligonucleotides: a new therapeutic approach].
Guinot P; Temsamani J
Pathol Biol (Paris); 1998 May; 46(5):347-54. PubMed ID: 9769897
[TBL] [Abstract][Full Text] [Related]
16. Technology evaluation: AVI-4126, AVI BioPharma.
Stephens AC
Curr Opin Mol Ther; 2004 Oct; 6(5):551-8. PubMed ID: 15537057
[TBL] [Abstract][Full Text] [Related]
17. INGN-201. Introgen Therapeutics.
Brukner I
Curr Opin Investig Drugs; 2001 Dec; 2(12):1776-85. PubMed ID: 11892946
[TBL] [Abstract][Full Text] [Related]
18. [Basics of antisense oligonucleotide therapy and current therapeutical strategies in urology].
Kausch I; Böhle A
Aktuelle Urol; 2003 Dec; 34(7):458-68. PubMed ID: 14655082
[TBL] [Abstract][Full Text] [Related]
19. British Biotech and MethylGene sign agreement on Phase II antisense drug.
Expert Rev Anticancer Ther; 2002 Feb; 2(1):6. PubMed ID: 12113069
[No Abstract] [Full Text] [Related]
20. Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer.
Dean E; Jodrell D; Connolly K; Danson S; Jolivet J; Durkin J; Morris S; Jowle D; Ward T; Cummings J; Dickinson G; Aarons L; Lacasse E; Robson L; Dive C; Ranson M
J Clin Oncol; 2009 Apr; 27(10):1660-6. PubMed ID: 19237630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
